“When it comes to getting tested, people are often reluctant due to the difficulty of testing”. It is precisely in view of this observation that Claude Hennion decided, together with other experts from the scientific and clinical community, to found Oncodiag in 2013. The main objective is to allow many patients to be evaluated thanks to non-invasive but equally effective solutions. , with priority being bladder cancer, colorectal cancer and prostate cancer. “For example, for bladder cancer, patients are required to have a checkup every 3 months with a camera that sits directly in the bladder. It’s too unpleasant for them, so some don’t come back to get tested. But without screening tests, cancer cannot be cured. laments Claude Hennion.
Urodiag, the first non-invasive test for bladder cancer screening
To address this problem, Oncodiag has developed an innovative solution that responds to a real medical need. “Being less adhesive to the bladder walls than normal cells, tumor cells will detach more easily and end up in the urine”. Thus, the patient simply has to provide a urine sample which will then be filtered and then analyzed by PCR to determine the genetic signature of the cells. On the market since the beginning of 2023, the Urodiag test has received the green light from the French Federation of Urology, which represents a true guarantee of quality and efficacy.
If there is a suitable solution for bladder cancer, Oncodiag now wants to continue its research for prostate cancer and colorectal cancer. “Urologists have found that 30% of removed prostates do not need to be removed and only require monitoring. Above all, we want to carry out a rigorous screening and give an indication of the level of aggressiveness in order to reduce prostate ablations as much as possible”. says Claude Hennion.
This content was produced in association with OpenMedias. The BFM Business editorial team was not involved in the production of this content.
Source: BFM TV
